Vaishali Pharma [VAISHALI] vs Lotus Eye Hospital [LOTUSEYE] Detailed Stock Comparison
Vaishali Pharma
NSE
Loading...
Lotus Eye Hospital
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Vaishali Pharma wins in 9 metrics, Lotus Eye Hospital wins in 9 metrics, with 0 ties. Both stocks appear equally matched on key metrics.
View Metrics Details
Vital Metrics Comparison
| Metric | Vaishali Pharma | Lotus Eye Hospital | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 187.33 | 379.19 | Vaishali Pharma |
| Price-to-Book Ratio | 2.34 | 4.25 | Vaishali Pharma |
| Debt-to-Equity Ratio | 18.98 | 5.72 | Lotus Eye Hospital |
| PEG Ratio | N/A | -28.44 | N/A |
| EV/EBITDA | -181.07 | 73.25 | Vaishali Pharma |
| Profit Margin (TTM) | 0.38% | 1.32% | Lotus Eye Hospital |
| Operating Margin (TTM) | 5.16% | 4.86% | Vaishali Pharma |
| EBITDA Margin (TTM) | 5.16% | 4.86% | Vaishali Pharma |
| Return on Equity | 1.26% | 1.23% | Vaishali Pharma |
| Return on Assets (TTM) | 0.74% | 1.06% | Lotus Eye Hospital |
| Free Cash Flow (TTM) | $-183.43M | $-21.28M | Lotus Eye Hospital |
| 1-Year Return | -46.57% | 70.35% | Lotus Eye Hospital |
| Price-to-Sales Ratio (TTM) | 1.40 | 5.04 | Vaishali Pharma |
| Enterprise Value | $1.54B | $2.54B | Lotus Eye Hospital |
| EV/Revenue Ratio | 1.47 | 5.05 | Vaishali Pharma |
| Gross Profit Margin (TTM) | 1.47% | 49.70% | Lotus Eye Hospital |
| Revenue per Share (TTM) | $8 | $24 | Lotus Eye Hospital |
| Earnings per Share (Diluted) | $0.06 | $0.32 | Lotus Eye Hospital |
| Beta (Stock Volatility) | 0.27 | 0.42 | Vaishali Pharma |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Vaishali Pharma vs Lotus Eye Hospital Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Vaishali Pharma | -1.23% | -1.13% | -7.94% | -3.73% | -7.56% | -36.20% |
| Lotus Eye Hospital | 0.11% | 4.11% | -3.96% | 62.10% | 85.79% | 76.55% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Vaishali Pharma | -46.57% | 15.90% | 204.01% | 168.79% | 168.79% | 168.79% |
| Lotus Eye Hospital | 70.35% | 64.72% | 304.44% | 772.43% | 576.68% | 242.61% |
News Based Sentiment: Vaishali Pharma vs Lotus Eye Hospital
Vaishali Pharma
News based Sentiment: NEGATIVE
October was a difficult month for Vaishali Pharma, with declining income, concerning financial ratios, and a negative analyst outlook. While there were some positive price movements and a bulk deal, the overall trend suggests increased risk and warrants investor caution. The combination of these factors makes this a significant month for the company's investment story.
Lotus Eye Hospital
News based Sentiment: POSITIVE
October was a positive month for Lotus Eye Hospital, with the opening of a new center, a share price increase, and a 'Strong Buy' recommendation from Bazaartrend. While the P/E ratio remains high, the overall narrative points to continued growth and investor confidence.
Performance & Financial Health Analysis: Vaishali Pharma vs Lotus Eye Hospital
| Metric | VAISHALI | LOTUSEYE |
|---|---|---|
| Market Information | ||
| Market Cap | ₹1.51B | ₹2.54B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 270,987 | 28,264 |
| 90 Day Avg. Volume | 348,974 | 188,855 |
| Last Close | ₹11.23 | ₹122.27 |
| 52 Week Range | ₹10.30 - ₹24.91 | ₹54.99 - ₹139.20 |
| % from 52W High | -54.92% | -12.16% |
| All-Time High | ₹24.91 (Oct 14, 2024) | ₹139.20 (Sep 03, 2025) |
| % from All-Time High | -54.92% | -12.16% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.31% | 0.05% |
| Quarterly Earnings Growth | -0.25% | -0.13% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.01% |
| Operating Margin (TTM) | 0.05% | 0.05% |
| Return on Equity (TTM) | 0.01% | 0.01% |
| Debt to Equity (MRQ) | 18.98 | 5.72 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹4.79 | ₹28.54 |
| Cash per Share (MRQ) | ₹0.14 | ₹1.98 |
| Operating Cash Flow (TTM) | ₹-326,443,000 | ₹5.77M |
| Levered Free Cash Flow (TTM) | ₹8.17M | ₹7.39M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | ₹0.00 |
Valuation & Enterprise Metrics Analysis: Vaishali Pharma vs Lotus Eye Hospital
| Metric | VAISHALI | LOTUSEYE |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 187.33 | 379.19 |
| Forward P/E | N/A | N/A |
| PEG Ratio | N/A | -28.44 |
| Price to Sales (TTM) | 1.40 | 5.04 |
| Price to Book (MRQ) | 2.34 | 4.25 |
| Market Capitalization | ||
| Market Capitalization | ₹1.51B | ₹2.54B |
| Enterprise Value | ₹1.54B | ₹2.54B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.47 | 5.05 |
| Enterprise to EBITDA | -181.07 | 73.25 |
| Risk & Other Metrics | ||
| Beta | 0.27 | 0.42 |
| Book Value per Share (MRQ) | ₹4.79 | ₹28.54 |
Financial Statements Comparison: Vaishali Pharma vs Lotus Eye Hospital
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | VAISHALI | LOTUSEYE |
|---|---|---|
| Revenue/Sales | ₹311.02M | ₹135.17M |
| Cost of Goods Sold | ₹306.45M | ₹67.99M |
| Gross Profit | ₹4.58M | ₹67.18M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹1.33M | ₹6.57M |
| EBITDA | ₹9.89M | ₹16.64M |
| Pre-Tax Income | ₹-56.02M | ₹7.30M |
| Income Tax | ₹-13.10M | ₹1.85M |
| Net Income (Profit) | ₹-42.93M | ₹5.45M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | VAISHALI | LOTUSEYE |
|---|---|---|
| Cash & Equivalents | ₹17.11M | ₹20.11M |
| Total Current Assets | ₹1.04B | ₹115.70M |
| Total Current Liabilities | ₹400.53M | ₹74.25M |
| Long-Term Debt | ₹46.19M | ₹20.27M |
| Total Shareholders Equity | ₹649.16M | ₹600.00M |
| Retained Earnings | ₹157.29M | ₹143.09M |
| Property, Plant & Equipment | ₹0 | ₹442.83M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | VAISHALI | LOTUSEYE |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | VAISHALI | LOTUSEYE |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 270,987 | 28,264 |
| Average Daily Volume (90 Day) | 348,974 | 188,855 |
| Shares Outstanding | 130.46M | 20.80M |
| Float Shares | 74.91M | 6.87M |
| % Held by Insiders | N/A | 0.65% |
| % Held by Institutions | N/A | 0.00% |
Dividend Analysis & Yield Comparison: Vaishali Pharma vs Lotus Eye Hospital
| Metric | VAISHALI | LOTUSEYE |
|---|---|---|
| Last 12-Month Dividend | N/A | ₹0.00 |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | ₹0.33 |
| 3-Year Avg Dividend Yield | N/A | 0.66% |
| 3-Year Total Dividends | N/A | ₹1.00 |
| Ex-Dividend Date | N/A | Sep 18, 2023 |